Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery
This study tests neoadjuvant therapy, which is treatment given before the main treatment, using a drug called AK104 combined with other medicines (nab-paclitaxel and carboplatin) for early-stage cervical cancer. Cervical cancer is a disease where cells in the cervix, the lower part of the uterus, grow uncontrollably. This study focuses on women who want to keep their ability to have children. The main goals are to see if the treatment is safe and how well it works.
Eligibility: Women aged 18-45 with specific types of early-stage cervical cancer, no previous cancer treatment, and good health are needed. They should be willing to give tissue and blood samples for research.
- đź•’ The study could involve several visits and tests.
- đź’Š Participants may experience side effects from the drugs.
- đź’° There may be compensation for time and travel.
Study details
NCT06209294
Xiaohua Wu
24 January 2024
Not finding the right Trial?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
FAQs
Learn more about clinical trials
What is a clinical trial?
Why should I take part in a clinical trial?
How long does a clinical trial take place?
Do I get compensated for taking part in clinical trials?
How safe are clinical trials?
Study Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.